Your browser doesn't support javascript.
loading
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell, Keith J; Mordant, Francesca L; Amarilla, Alberto A; Modhiran, Naphak; Liang, Benjamin; Li, Zheyi; Wijesundara, Danushka K; Lackenby, Julia A; Griffin, Paul; Bennet, Jillian K; Hensen, Luca; Zhang, Wuji; Nguyen, Thi H O; Tran, Mai H; Tapley, Peter; Barnes, James; Reading, Patrick C; Kedzierska, Katherine; Ranasinghe, Charani; Subbarao, Kanta; Watterson, Daniel; Young, Paul R; Munro, Trent P.
Afiliação
  • Chappell KJ; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia; Australian Infectious Diseases Research Centre, The University of Queensland,
  • Mordant FL; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia.
  • Amarilla AA; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia.
  • Modhiran N; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia.
  • Liang B; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia.
  • Li Z; Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
  • Wijesundara DK; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia.
  • Lackenby JA; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia.
  • Griffin P; Nucleus Network Brisbane Clinic, Herston, QLD, Australia; Department of Infectious Diseases, Mater Health, QLD, Australia; School of Medicine, The University of Queensland, St Lucia, QLD, Australia.
  • Bennet JK; Tanawell Consulting, Melbourne, VIC, Australia.
  • Hensen L; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia.
  • Zhang W; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia.
  • Nguyen THO; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia.
  • Tran MH; Agilex Biolabs, Thebarton, SA, Australia.
  • Tapley P; Agilex Biolabs, Thebarton, SA, Australia.
  • Barnes J; WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Reading PC; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia; WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Kedzierska K; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia.
  • Ranasinghe C; Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
  • Subbarao K; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia; WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Watterson D; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia; Australian Infectious Diseases Research Centre, The University of Queensland,
  • Young PR; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia; Australian Infectious Diseases Research Centre, The University of Queensland,
  • Munro TP; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia.
EBioMedicine ; 97: 104842, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37865043
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Infecções por HIV / COVID-19 Limite: Aged / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Infecções por HIV / COVID-19 Limite: Aged / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article